Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Open accessAbstract
Purpose To investigate whether semaglutide increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in the general population.Design This retrospective cohort study used a deidentified global electronic medical records database. The enrollment period was extended from January 2017 to August 2023, with observations concluding in August 2024.Participants This study included individuals with type 2 diabetes mellitus (T2DM) or obesity. They were further categorized into T2DM-only, obesity-only, and T2DM with obesity groups to assess the differences among these subgroups. The effects of semaglutide were compared with those of glucose-lowering or weight-loss medications other than glucagon-like peptide receptor agonists.Methods Patient data were obtained from 160 health care organizations across 21 countries. Outcomes were evaluated at 1, 2, and 3 years of follow-up. A 1:1 propensity score matching was performed to balance age, sex, body mass index, hemoglobin A1C, medications, and underlying comorbidities. Cox regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs).Main outcome measures The occurrence of NAION.Results The final analysis included 37 314 participants with T2DM only, 129 690 participants with obesity only, and 130 216 participants with both T2DM and obesity. The results indicated that the administration of semaglutide was not associated with the development of NAION in the T2DM-only group (1-year follow-up: HR, 2.32; 95% CI, 0.60-8.97; 2 years: HR, 2.31; 95% CI, 0.86-6.17; 3 years: HR, 1.51; 95% CI, 0.71-3.25), the obesity-only group (1-year follow-up: HR, 0.41; 95% CI, 0.08-2.09; 2 years: HR, 0.67; 95% CI, 0.20-2.24; 3 years: HR, 0.72; 95% CI, 0.24-2.16), and the T2DM with obesity group (1 year follow-up: HR, 0.81; 95% CI, 0.42-1.57; 2 years: HR, 1.2; 95% CI, 0.74-1.94; 3 years: HR, 1.19; 95% CI, 0.78-1.82).Conclusions The findings suggest that semaglutide may not be associated with an increased risk of NAION in the general population. Therefore, avoidance of semaglutide based solely on concerns regarding the risk of NAION may not be warranted because its potential benefits for blood glucose control and cardiovascular health likely outweigh its potential risks.Financial disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The association between optic nerve and retinal disorders and potent GLP-1 receptor agonists or tirzepatide has not been confirmed by other studies.
“Although such an association has not been confirmed by other studies, 92,93”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [92]
The Discussion (page unavailable) reports that this study did not find an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide, so it supports the narrower point that an earlier reported association was not confirmed here. The paper does not establish the broader claim about retinal disorders, other potent GLP-1 receptor agonists, or tirzepatide. (LLM, conf=0.87)
Experimental — accuracy not yet measuredStudies show conflicting associations between semaglutide or GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy (NAION).
“Studies show conflicting associations.2,3,4,5,6,7,8,9”
From New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes (2026) · cites this paper as [6]
Large observational analyses reported similar 2- to 3-fold risks of NAION with GLP-1 receptor agonists, whereas others observed attenuated or null associations.
“Large observational analyses reported similar 2- to 3-fold risks,2,3,4,5 whereas others observed attenuated or null associations.6,7,8,9”
From New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes (2026) · cites this paper as [6]
A separate study found no significant difference in the risk of NAION in high BMI and diabetic patients prescribed semaglutide.
“A separate study evaluated this relationship among patients from 21 different countries and found no significant difference in the risk of NAION in high BMI and diabetic patients prescribed semaglutide.”
From The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [32]
The study's conclusions align with those of Chou et al, who found no association between semaglutide and NAION.
“Our conclusions align with those of Chou et al, who found no association between semaglutide and NAION.”
From The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [32]
Some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs.
“some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs (94, 95).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works
Incidence of Nonarteritic Anteripr Ischemic Optic Neuropathy
HATTENHAUER, M. G., LEAVITT, J. A., HODGE, D. O., GRILL, R., & GRAY, D. T. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70999-7 · Cited by 437 · see citing works
Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy
Hayreh, S. S., Joos, K. M., Podhajsky, P. A., & Long, C. R. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72557-7 · Cited by 402 · see citing works
Johnson, L. N., & Arnold, A. C. (1994) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199403000-00011 · Cited by 359 · see citing works
Biousse, V., & Newman, N. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1413352 · Cited by 349 · see citing works
Anterior Ischemic Optic Neuropathy
Beck, R. W., Servais, G. E., & Hayreh, S. S. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33263-4 · Cited by 344 · see citing works
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318 · see citing works
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176 · see citing works
Nonarteritic Anterior Ischemic Optic Neuropathy: A Case-Control Study of Potential Risk Factors
Jacobson, D. M. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160573008 · Cited by 162 · see citing works
Cup-Disc Ratio and Ischemic Optic Neuropathy
Doro, S., & Lessell, S. (1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050080055019 · Cited by 153 · see citing works
Cestari, D. M., Gaier, E. D., Bouzika, P., Blachley, T. S., De Lott, L. B., Rizzo, J. F., Wiggs, J. L., Kang, J. H., Pasquale, L. R., & Stein, J. D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.08.017 · Cited by 125 · see citing works
Ischemic Optic Neuropathy Decompression Trial Twenty-Four–Month Update
Ischemic Optic Neuropathy Decompression Trial Research Group (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.6.793 · Cited by 115 · see citing works
Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93 · see citing works
Young Adults With Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study
Hamann, S., Malmqvist, L., Wegener, M., Fard, M. A., Biousse, V., Bursztyn, L. L. C. D., Citirak, G., Costello, F., Crum, A. V., Digre, K. B., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.03.052 · Cited by 85 · see citing works
Optic Neuropathy in Patients Using Amiodarone
Purvin, V. A. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.5.696 · Cited by 71 · see citing works
Lee, Y.-C., Wang, J., Huang, T., & Tsai, R. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.08.006 · Cited by 43 · see citing works
Dzaye, O. D. A., Berning, P., Razavi, A. C., Adhikari, R., Jha, K. K., Nasir, K., Ayers, J. W., Mortensen, M. B., & Blaha, M. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936651 · Cited by 26 · see citing works
Pan, S., Su, E.-L., Huang, C., Chuang, S., Chiang, C., Chen, C., & Cheng, H. (2024) · Age and Ageing · doi:10.1093/ageing/afae175 · Cited by 23 · see citing works
Self-citationGlucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Gaw, C. E., Hays, H. L., Kemp, C. A., Kistamgari, S., Spiller, H. A., Rine, N. I., Rhodes, A. L., Zhu, M., & Smith, G. A. (2024) · Journal of Medical Toxicology · doi:10.1007/s13181-024-00999-x · Cited by 18 · see citing works
Validity of Administrative Coding for Nonarteritic Ischemic Optic Neuropathy
Hamedani, A. G., Kim, D. S., Chaitanuwong, P., Gonzalez, L. A., Moss, H. E., & DeLott, L. B. (2024) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002163 · Cited by 18 · see citing works
Hor, M., Baradeiya, A. M., Qasim, H., Nasr, M., & Mohammad, A. (2022) · Cureus · doi:10.7759/cureus.27642 · Cited by 13 · see citing works
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 13 · see citing works
Weight loss medication prescription prevalence in the active component, 2018-2023.
Lorei, N. C., Stahlman, S. L., Oh, G., & Wells, N. Y. (2024) · PubMed Central · Cited by 7 · see citing works
Flagged first, then by citations
2 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123 · see citing works
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16316 · Cited by 85 · see citing works
The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Abbass, N. J., Nahlawi, R., Shaia, J. K., Allan, K. C., Kaelber, D. C., Talcott, K. E., & Singh, R. P. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.02.025 · Cited by 78 · see citing works
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70 · see citing works
Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., Khadke, S., Kumar, A., Patel, T., Kosiborod, M. N., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26321 · Cited by 63 · see citing works
Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Wang, L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26327 · Cited by 51 · see citing works
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41 · see citing works
Amini, A., Hamann, S., & Larsen, M. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17473 · Cited by 30 · see citing works
GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis
Amaral, D. C., Guedes, J., Cruz, M. M., Cheidde, L., Nepomuceno, M., Magalhães, P., Brazuna, R., Mora-Paez, D. J., Huang, P., Razeghinejad, R., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.024 · Cited by 29 · see citing works
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40 · see citing works
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 32 · see citing works
Tesfaye, H., Paik, J. M., Wexler, D. J., Carreno-Galeano, J. T., Yu, E. W.-Y., Freedman, A., Rizzo, J. F., & Patorno, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70200 · Cited by 18 · see citing works
Zhao, T., Zheng, L., Feng, Y., Lao, M., Huang, Y., & Wu, G. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04096-7 · Cited by 19 · see citing works
Xie, Z., Yang, Z., Tian, D., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1618079 · Cited by 20 · see citing works
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 16 · see citing works
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 17 · see citing works
Heberer, K., Bress, A. P., Cogill, S., Maldonado, A. I., Kim, S. H., Nallamshetty, S., Chen, Y. Q., Shih, M.-C., Lynch, J. A., & Lee, J. S. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.6262 · Cited by 18 · see citing works
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 16 · see citing works
Feldman-Billard, S. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101664 · Cited by 12 · see citing works
Glucagon-like peptide-1 receptor agonists and the eye
Zhang, D. L., & Finn, A. P. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001137 · Cited by 12 · see citing works
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y.-H. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 10 · see citing works
Ocular Effects of GLP-1 Receptor Agonists: A Review of Current Evidence and Safety Concerns
Albanese, G. M., Visioli, G., Alisi, L., Giovannetti, F., Lucchino, L., Armentano, M., Catania, F., Marenco, M., & Gharbiya, M. (2025) · Diabetology · doi:10.3390/diabetology6100117 · Cited by 10 · see citing works
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Carter, P., Simó, R., Lövestam‐Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P. I., Gamble, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70160 · Cited by 9 · see citing works
Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy
Abdelaal, A., Serhan, H. A. A., Alsaadi, M., Yaldo, L. M., Gaier, E. D., & Elhusseiny, A. M. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.02.013 · Cited by 9 · see citing works
Maceroni, M., Sasso, P., Giarletti, M., Bruno, V., & Minnella, A. M. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721251331655 · Cited by 8 · see citing works
Özbek, L., Güldan, M., Fidan, D. G., Abdel‐Rahman, S. M., & Kanbay, M. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.05.011 · Cited by 8 · see citing works
Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication
Gaćina, D. L., Vidović, T., Oreb, N. V., Matković, L., & Jandroković, S. (2025) · Reports — Medical Cases Images and Videos · doi:10.3390/reports8030149 · Cited by 8 · see citing works
Kapantais, D., & Tsoutsanis, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248792 · Cited by 8 · see citing works
Noh, Y., Yin, H., Ghezala, I. B., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2026) · Diabetes Care · doi:10.2337/dc25-2577 · Cited by 9 · see citing works
Conflicting Results—Need for More Transparent and Reproducible Research
Cai, C. X., Hribar, M. R., & Nishimura, A. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0350 · Cited by 8 · see citing works
Lixi, F., Calabresi, V., Cukurova, F., & Giannaccare, G. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s531930 · Cited by 7 · see citing works
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 7 · see citing works
Lieberman, R. A., Korona-Bailey, J., Banaag, A. L., Fuhrman, B. J., Corrado, R., & Koehlmoos, T. P. (2025) · Military Medicine · doi:10.1093/milmed/usaf522 · Cited by 7 · see citing works
Dhivagaran, T., Butt, F. R., Arunasalam, L., Bae, I., Mikhail, D., Tao, B. K.-L., Xie, J. S., Balas, M., Popovic, M. M., & Margolin, E. (2026) · Neurology · doi:10.1212/wnl.0000000000214864 · Cited by 7 · see citing works
DeParis, S. W., Oke, I., Gaier, E. D., Moss, H. E., MacIntosh, P. W., Gilbert, A. L., Dinkin, M., & Chen, J. J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.008 · Cited by 8 · see citing works
Nadeem, N., Issa, R. M. A., Shah, A., Wardeh, R., Rashid, F., Abdelgadir, E., & Bashier, A. M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.07.002 · Cited by 7 · see citing works
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review
Ramos, R. A. H., Ortiz, M., Krieger, S. D., & Secades, D. (2025) · Cureus · doi:10.7759/cureus.89656 · Cited by 7 · see citing works
A real-world population-based study on the association between cataracts and antipsychotics
Lakhani, M., Kwan, A. T. H., Chaudry, E., Popovic, M. M., Xie, J. S., Rai, A., Rai, A. S., Margolin, E., & McIntyre, R. S. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.05.021 · Cited by 6 · see citing works
Are synthetic incretins associated with ischaemic optic neuropathy?
Gregory, V., & Mollan, S. P. (2025) · Eye · doi:10.1038/s41433-025-03718-0 · Cited by 6 · see citing works
NAION risk with semaglutide: what we know so far
Hsu, A. Y., Wang, Y., Lin, C., Hsia, N.-Y., Shao, Y.-C., Chiang, C.-C., Chen, H., Tsai, Y., & Wei, J. C.-C. (2025) · Eye · doi:10.1038/s41433-025-03833-y · Cited by 6 · see citing works
Self-citationGullaksen, S., Vernstrøm, L., Sørensen, S. S., Funck, K. L., Petersen, L., Bek, T., Poulsen, P. L., & Laugesen, E. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109039 · Cited by 5 · see citing works
Vilsbøll, T., Kumar, D. A., Aiello, L. P., Rönnbäck, C., Stellfeld, M., & Larsen, L. M. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328729 · Cited by 7 · see citing works
Chrzanowski, J., Walicka, M., Burzyński, J., Zaraś, M., Michalak, A., & Fendler, W. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005064 · Cited by 6 · see citing works
GLP-1 RAs and Nonarteritic Anterior Ischemic Optic Neuropathy—Making Sense of the Data
Etminan, M., Sodhi, M., & Maberley, D. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6181 · Cited by 5 · see citing works
Goldenberg, R., Aronson, R., & Trinacty, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70013 · Cited by 5 · see citing works
Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
Malerbi, F. K., & Bertoluci, M. C. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00622-9 · Cited by 5 · see citing works
Semaglutide and the retina: Weighing evidence against concern
Muzurović, E. M., Zečević, K., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109148 · Cited by 4 · see citing works
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 5 · see citing works
Chen, J.-W., Yu, F. T.-E., Chen, H.-A., Huang, T.-F., Chen, H.-S., & Wu, T.-E. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101740 · Cited by 4 · see citing works
Ong, S. S. Y., & Pasquel, F. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26336 · Cited by 2 · see citing works
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3 · see citing works
Varghese, D., Abdelsalam, D., Ibrahim, S., Lee, A. G., & Bhatti, M. T. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.01.001 · Cited by 2 · see citing works
Lawrence, A. L., Savino, P. J., & Danesh-Meyer, H. V. (2026) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70061 · Cited by 3 · see citing works
Robertson, C. M., Fung, D., Smith, K. H., Lai, K. E., Guniganti, R., Rizzo, J. F., & Lao, K. C. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.07.036 · Cited by 2 · see citing works
Semaglutide and Risk of NAION—Additional Insights
Rizzo, J. F., & Carreno-Galeano, J. T. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0005 · Cited by 2 · see citing works
Liu, L. Q., Mohan, S., & Wu, L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf541 · Cited by 2 · see citing works
Association of Semaglutide and NAION Reviewed
Klonoff, D. C., & Gombar, S. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1823 · Cited by 1 · see citing works
Barnett, M. J., Ibe, F. O., & Lam, J. (2026) · Cureus · doi:10.7759/cureus.100953 · Cited by 1 · see citing works
Endocrinology: What You May Have Missed in 2025
Escudero, C., Havranek, K., Cruz, M. M., & Batch, B. C. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00925 · Cited by 1 · see citing works
Al-Harbi, F. A., Alkuwaiti, M. A., Alaql, Y. B., Alsaif, A. K., Alessa, A. A., Alharbi, M., Alfalah, M., Alnaaim, S. A., AlHaddad, S. M., & Azzam, A. Y. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70406 · Cited by 1 · see citing works
The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations
Lampsas, S., Chardalia, G.-M., Agapitou, C., Papastamopoulos, K., Theodossiadis, P., Siasos, G., Oikonomou, E., Lambadiari, V., & Chatziralli, I. (2026) · Biomedicines · doi:10.3390/biomedicines14051057 · Cited by 2 · see citing works
Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists
Lixi, F., Troisi, M., Calabresi, V., Giagoni, A., Rossi, C., Timofte-Zorila, M.-M., Tarași, T.-C., Vitiello, L., Tomi, M.-I., Gheorghe, A. G., et al. (2026) · Vision · doi:10.3390/vision10020029 · Cited by 2 · see citing works
Lampsas, S., Agapitou, C., Oikonomou, E., Siasos, G., Theodossiadis, P., Tsivgoulis, G. K., Lambadiari, V., & Chatziralli, I. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07291-4 · Cited by 1 · see citing works
Atypical retrobulbar optic neuropathy after semaglutide escalation
Channabasappa, S., Gupta, R. D., Chandran, V., & Prasad, S. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag108 · Cited by 2 · see citing works
Kakkar, A. K., Payra, S., & Charaya, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70952 · Cited by 1 · see citing works
Andreão, F. F., Amaral, D. C., Magalhães, P. L. M., Cheidde, L., Louzada, R. N., Monteiro, M. L. R., & Santos, D. H. (2026) · AJO International · doi:10.1016/j.ajoint.2026.100275 · Cited by 1 · see citing works
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
Ueda, P., Svanström, H., Söderling, J. K., Pazzagli, L., Wintzell, V., Eliasson, B., Hviid, A. P., & Pasternak, B. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-02096 · Cited by 2 · see citing works
Khani, E., Asham, H., Rezabakhsh, A., Babaei, S., & Entezari‐Maleki, T. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70248 · Cited by 1 · see citing works
Zhu, H., & Zhao, K. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.02.024 · Cited by 1 · see citing works
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3 · see citing works
Chou, C.-C., Pan, S., & Weng, C. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.02.023
Self-citationAvances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Chou, C.-C., Pan, S., & Weng, C. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.03.010
Self-citationAbbass, N. J., Allan, K. C., Talcott, K. E., & Singh, R. P. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.06.025
Hsu, A. Y., Lin, C., Shao, Y.-C., Tsai, Y., Wang, Y., & Wei, J. C.-C. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.053
Self-citationAdvances in materials science for ocular diseases induced by cardiovascular risk factors
Chen, P., Zheng, B., Wang, P., Liu, H., & Pei, H. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1618232
Dziewierz, A., & Siudak, Z. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70128
Heberer, K. R., Bress, A. P., Cogill, S., Maldonado, A. I., Kim, S. H., Nallamshetty, S., Chen, Y. Q., Shih, M.-C., Lynch, J. A., & Lee, J. S. (2025) · medRxiv · doi:10.1101/2025.09.15.25335753
Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane
Chen, P.-H., Abood, S., & Bloom, S. H. (2025) · Microvascular Research · doi:10.1016/j.mvr.2025.104880
Weng, C., Bennett, C. L., Magagnoli, J., Chou, C., & Chan, P. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70293
Self-citationNAION (non-arteritic anterior ischemic optic neuropathy): Focus on semaglutide
Hussain, A., Gray, J. P., & Ray, S. D. (2025) · Side effects of drugs annual · doi:10.1016/bs.seda.2025.10.007
Jarrett, E., Muayad, J., Ryu, B. U., Lee, A. G., & Gupta, P. K. (2026) · Clinical ophthalmology · doi:10.2147/opth.s581826
Sharma, A., Wu, L., Bloom, S., Stanga, P. E., Cai, C. X., Singh, R. P., Verghese, S., Chandrakanth, P., Prabha, D., & Rezaei, K. A. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260114-01
Maideen, N. M. P., Rashid, S. A., Balasubramanian, R., & Amirthalingam, P. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2659_25
HbA1c kinetics as a prognostic marker of ophthalmic risk in GLP-1 receptor agonist therapy
Margoni, A., Papavassiliou, K. A., & Papavassiliou, A. G. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100468
Danesh-Meyer, H. V., & Rizzo, J. F. (2026) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70096
Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, for Ocular Health
Nguyen, A., Zhu, A., & Khouri, A. S. (2026) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683261456222
Abboud, I., Madani, R., Chacko, J. G., Phillips, P. H., Elhusseiny, A. M., & Gaier, E. D. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.06.014
STOUGAARD, E. B., & Rossing, P. R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag131
Park, J., Kim, J. H., Kim, Y. S., Lim, G., Song, H. J., Rhee, S. Y., Hwang, S., Cho, D. H., Kim, M. S., Kim, B., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71065
Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy
Reynolds, K. R., O’Malley, K. M., Roy, J. A., & Dave, C. V. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00860
What an Ophthalmologist Should Know about the Side Effects of “Ozempic” and its Analogues
Николаевич, Т. В., Полунина, Е. Г., Trubilin, А. V., Кечин, Е. В., Анджелова, Д. В., Konovalov, M. E., Privezentseva, T. A., & Fedoseyev, Y. B. (2026) · Ophthalmology in Russia · doi:10.18008/1816-5095-2026-2-234-241
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Lee, J. J., Brothers, T. N., Kim, L. A., Ward, K. E., Yusuf, H., & Wen, X. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.08.029
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025
Смена парадигмы лечения сахарного диабета 2-го типа – от метаболической коррекции к органопротекции
Мохорт, Т. В. (2026) · Кардиология в Беларуси · doi:10.34883/pi.2026.18.3.009
Sun, H., Xin, X., Yan, J., & Huang, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71358
Uddaraju, M., Penmatsa, S., Laveti, S. N., & Vaishali, K. V. (2024) · Journal of ophthalmology clinics and research. · doi:10.4103/jocr.jocr_10_26
- Authors
- Chou, C.-C., Pan, S.-Y., Sheen, Y.-J., Lin, J.-F., Lin, C.-H., Lin, H.-J., Wang, I.-J., & Weng, C.-H.
- Affiliations
- National Yang Ming Chiao Tung University (TW)
- Taichung Veterans General Hospital (TW)
- Fu Jen Catholic University (TW)
- China Medical University (TW)
- Brown University (US)
- Corresponding author
- Weng, Chien-Hsiang
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2025-04
- Volume
- 132
- Issue
- 4
- Pages
- 381-388
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W4403999311
- Semantic Scholar
- aa78f19846444c79d2357846888082679c194abf
- Cited by
- 104
- References
- 26
- Citations by year
- 2026: 46 · 2025: 56 · 2024: 2
- FWCI
- 34.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Taichung Veterans General Hospital (TCVGH-1136902B)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- semaglutide, nonarteritic anterior ischemic optic neuropathy, type 2 diabetes, obesity, drug safety, adverse event risk, anti-obesity drugs, glucose-lowering medications, propensity score matching, hazard ratio, real-world evidence
- MeSH terms
- Semaglutide, Adult, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Retrospective Studies, Risk Factors, Incidence, Optic Neuropathy, Ischemic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
